论文部分内容阅读
目的分析采用噻托溴铵联合布地奈德福莫特罗治疗慢性阻塞性肺疾病(慢阻肺)的临床效果。方法 102例慢阻肺患者,采用随机数字表法分为观察组和对照组,各51例。对照组仅采用布地奈德福莫特罗进行吸入治疗,观察组患者在对照组基础上联合噻托溴铵进行治疗,对两组患者治疗前后呼吸功能变化情况进行观察记录。结果治疗6个月后,观察组患者FEV1上升至(1.26±0.20)%,FEV1%pred上升至(58.10±11.36)%;对照组患者FEV1上升至(1.13±0.19)%,FEV1%pred上升至(53.85±9.91)%。治疗后两组患者的肺功能均显著优于治疗前(P<0.05),且观察组患者肺功能指标明显优于对照组(P<0.05)。观察组患者治疗前英国医学研究委员会呼吸困难量表(MMRC)评分为(2.59±0.71)分,治疗后下降至(1.65±0.85)分;对照组治疗前MMRC评分为(2.55±0.80)分,治疗后下降至(2.21±0.63)分。治疗后两组患者MMRC评分均明显优于治疗前(P<0.05),且观察组下降幅度明显优于对照组,差异具有统计学意义(P<0.05)。结论采用布地奈德福莫特罗联合噻托溴铵治疗慢阻肺,可显著改善患者的肺功能,并缓解呼吸困难症状,是一种有效的慢阻肺控制方案。
Objective To analyze the clinical effect of tiotropium combined with budesonide formoterol in the treatment of chronic obstructive pulmonary disease (COPD). Methods A total of 102 patients with chronic obstructive pulmonary disease (COPD) were divided into observation group and control group using random number table method, with 51 cases in each group. The control group was treated with inhaled budesonide formoterol alone. The patients in the observation group were treated with tiotropium on the basis of the control group, and the changes of respiratory function before and after treatment were observed and recorded in both groups. Results FEV1 increased to (1.26 ± 0.20)% and FEV1% pred increased to (58.10 ± 11.36)% in control group, FEV1 increased to (1.13 ± 0.19)% and FEV1% pred increased to (53.85 ± 9.91)%. The pulmonary function of the two groups after treatment was significantly better than before treatment (P <0.05), and the lung function indexes of the observation group were significantly better than the control group (P <0.05). The score of MMRC was (2.59 ± 0.71) in the observation group before treatment, and dropped to (1.65 ± 0.85) in the control group before treatment. The MMRC score in the control group was (2.55 ± 0.80) After treatment decreased to (2.21 ± 0.63) points. MMRC scores of the two groups were significantly better than those before treatment (P <0.05), and the decrease in the observation group was significantly better than that of the control group, the difference was statistically significant (P <0.05). Conclusion The combination of budesonide formoterol and tiotropium in the treatment of chronic obstructive pulmonary disease can significantly improve pulmonary function and alleviate the symptoms of dyspnea and is an effective control strategy for COPD.